Literature DB >> 18790174

Change of melanocortin receptor expression in rat kidney ischemia-reperfusion injury.

Y S Lee1, J J Park, K Y Chung.   

Abstract

OBJECTIVES: alpha-Melanocyte stimulating hormone (alpha-MSH) may ameliorate renal ischemia-reperfusion (I/R) injury. Recent data suggest that melanocortin receptors may be related to the anti-inflammatory and immunomodulating action for alpha-MSH. We designed this experiment to determine the renal distribution of alpha-MSH receptors; melanocortin-1 receptor (MC-1R) and melanocortin-3 receptor (MC-3R).
METHODS: Sprague-Dawley male rats (n = 24) were randomly divided into 2 groups: the sham (n = 2) and the operation groups with warm ischemia (n = 12). Animals in the operation group were subjected to 40 minutes of warm renal ischemia. Western blotting analyses and immunohistochemistry were employed to determine expression of MC-1R and MC-3R.
RESULTS: Expression of MC-1R and MC-3R was decreased on 1 day after reperfusion. Immunohistochemical study confirmed the findings of Western blot analysis.
CONCLUSIONS: The present study demonstrated novel renal expression of MC-1R and MC-3R, especially in the outer medulla, representative of the renal I/R injury. Our current study suggested that the mechanisms of action of alpha-MSH may significantly attenuate the renal I/R injury by specific kidney-targeted effects via MC-Receptors as well as by systemic cytokine effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18790174     DOI: 10.1016/j.transproceed.2008.07.101

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

Review 1.  The renaissance of corticotropin therapy in proteinuric nephropathies.

Authors:  Rujun Gong
Journal:  Nat Rev Nephrol       Date:  2011-12-06       Impact factor: 28.314

Review 2.  Leveraging melanocortin pathways to treat glomerular diseases.

Authors:  Rujun Gong
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

3.  Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model.

Authors:  D A C Botte; I L Noronha; D M A C Malheiros; T V Peixoto; S B V de Mello
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

4.  Effects of α-MSH on ischemia/reperfusion injury in the rat sciatic nerve.

Authors:  Erhan Turkoglu; Gökhan Serbes; Habibullah Dolgun; Sinem Oztuna; Ozlen T Bagdatoglu; Necat Yilmaz; Celal Bagdatoglu; Zeki Sekerci
Journal:  Surg Neurol Int       Date:  2012-07-14

5.  MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy.

Authors:  Yingjin Qiao; Anna-Lena Berg; Pei Wang; Yan Ge; Songxia Quan; Sijie Zhou; Hai Wang; Zhangsuo Liu; Rujun Gong
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

Review 6.  Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities.

Authors:  Mingyang Chang; Bohan Chen; James Shaffner; Lance D Dworkin; Rujun Gong
Journal:  Front Physiol       Date:  2021-02-24       Impact factor: 4.566

7.  α-Melanocyte stimulating hormone treatment in pigs does not improve early graft function in kidney transplants from brain dead donors.

Authors:  Willem G van Rijt; Niels Secher; Anna K Keller; Ulla Møldrup; Yahor Chynau; Rutger J Ploeg; Harry van Goor; Rikke Nørregaard; Henrik Birn; Jørgen Frøkiaer; Søren Nielsen; Henri G D Leuvenink; Bente Jespersen
Journal:  PLoS One       Date:  2014-04-11       Impact factor: 3.240

8.  ABT-719 for the Prevention of Acute Kidney Injury in Patients Undergoing High-Risk Cardiac Surgery: A Randomized Phase 2b Clinical Trial.

Authors:  Peter A McCullough; Elliott Bennett-Guerrero; Lakhmir S Chawla; Thomas Beaver; Ravindra L Mehta; Bruce A Molitoris; Ann Eldred; Greg Ball; Ho-Jin Lee; Mark T Houser; Samina Khan
Journal:  J Am Heart Assoc       Date:  2016-08-20       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.